Category: clinical study retractions

In February, the editor-in-chief of Food and Chemical Toxicology published an editorial calling for “Papers on potential toxic effects of COVID-19 vaccines.” Following this call, in April 2022, the journal – no stranger to Retraction Watch readers –  published an article titled “Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs.” 

At more than 16,000 words and more than 200 references, the article was submitted on February 9^th and accepted on April 8^th. It claims that “billions of lives are potentially at risk” with Covid-19 vaccines. 

Such an important statement should be supported by facts. But this is not at all the case. And yet the paper has been shared more than 45,000 times on social media, in ways that decrease trust in science and the COVID-19 vaccine, despite the robust evidence that it is both safe and efficient.

When a retracted paper is republished in a new journal, should it note the retraction?

A few readers have asked us that question as they forwarded a paper published in May in Environmental Research, an Elsevier title. The study, “Carbon dioxide rises beyond acceptable safety levels in children under nose and mouth covering: Results of an experimental measurement study in healthy children,” bore striking similarities to a paper by the same authors that was retracted from JAMA Pediatrics in July 2021. 

That retraction was the second for the paper’s first author, Harald Walach, who also lost an affiliation with a university in Poland. Walach tells us that he let the editor know about the JAMA Pediatrics retraction before he submitted the manuscript:

Researchers in Iran have lost a paper on Covid-19 infection in a two-month-old boy after the journal learned that they’d fabricated ethics approval for the article. 

It’s the 250th Covid-19 retraction by our count.

“Coronavirus disease 2019 in a 2-month-old male infant: a case report from Iran” appeared in December 2020 in Clinical and Experimental Pediatrics. The senior author of the paper was Sajjad Ahmadpour, of the Gastroenterology and Hepatology Diseases Research Center at Qom University of Medical Sciences.

According to the retraction notice (which doesn’t appear in the expected place but can be found here):

A journal has retracted a paper reporting the results of a clinical trial in which a drug cut COVID-19 hospitalization for men by 90%. 

The research group’s other work has attracted a lot of attention in Brazil – including praise from  president Jair Bolsonaro and criticism from research regulators – for their dramatic results. In a Twitter thread, one of the authors claimed, without evidence, that the journal “may have received bribery to persecute us and retract our study.”

The article, “Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial,” was published in Frontiers in Medicine last July and has been cited 15 times, according to Clarivate’s Web of Science. 

The study quickly attracted criticism, according to the retraction notice: